BREVAGen is the latest advance in assessing a woman’s unique risk of developing non-familial or sporadic breast cancer.
“The breast cancer screening process can
be arduous and confusing for patients because there are so many
screening options and test attributes to sort out,” Denise Barajas, MD, medical director at The Hewitt Center for Breast Wellness,
said.
“We can simplify the process by administering BREVAGen, which gives patients an accurate five-year and lifetime risk assessment for developing estrogen-positive breast cancer. By knowing each patient’s risk we can then develop personalized breast health and monitoring plans tailored to their specific risk and needs which will help us reduce the incidence of advanced breast cancer cases we see; this should help save lives.”
“We can simplify the process by administering BREVAGen, which gives patients an accurate five-year and lifetime risk assessment for developing estrogen-positive breast cancer. By knowing each patient’s risk we can then develop personalized breast health and monitoring plans tailored to their specific risk and needs which will help us reduce the incidence of advanced breast cancer cases we see; this should help save lives.”
BREVAGen is a predictive risk test that
more accurately identifies a woman’s unique risk of developing sporadic,
estrogen-positive breast cancer.
BREVAGen examines a woman’s clinical risk factors, such as their lifetime exposure to estrogen, combined with scientifically validated markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
BREVAGen examines a woman’s clinical risk factors, such as their lifetime exposure to estrogen, combined with scientifically validated markers to determine each patient’s personalized five-year and lifetime risk of developing breast cancer.
For more information about BREVAGen at The Hewitt Center for Breast Wellness, contact Catherine Krueger, 203-732-7233.
How BREVAGen Works
The BREVAGen predictive risk test is
administered in a physician’s office using a simple, non-invasive
“oral-swab.”
Physicians receive a comprehensive genetic risk prediction report to review with the patient. The patient’s risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called single nucleotide polymorphisms, with factors that comprise the patient’s clinical and reproductive history including current age, age at menarche, age at live first birth and race/ethnicity.
Physicians receive a comprehensive genetic risk prediction report to review with the patient. The patient’s risk of breast cancer is calculated by combining their relative risk score from seven genetic markers, called single nucleotide polymorphisms, with factors that comprise the patient’s clinical and reproductive history including current age, age at menarche, age at live first birth and race/ethnicity.
The BREVAGen test provides five-year and
lifetime predictive risk assessments to more accurately evaluate the
patient’s risk for developing sporadic breast cancer, regardless of
family history or previous indeterminate test results.
Clinically Validated
BREVAGen was proven superior in
determining breast cancer risk. Utilizing data from the U.S. Women’s
Health Initiative Clinical Trial, 3,300 women underwent breast
cancer assessment utilizing the BREVAGen test.
Of those 3,300 women, 1,664 were diagnosed with breast cancer and 1,636 were in the breast cancer-free control group. BREVAGen test results support current American Cancer Society, American Society of Clinical Oncology, and The National Comprehensive Cancer Network guidelines for prevention and early detection of breast cancer.
Of those 3,300 women, 1,664 were diagnosed with breast cancer and 1,636 were in the breast cancer-free control group. BREVAGen test results support current American Cancer Society, American Society of Clinical Oncology, and The National Comprehensive Cancer Network guidelines for prevention and early detection of breast cancer.
About The Hewitt Center for Breast Wellness at Griffin Hospital
The Hewitt Center for Breast Wellness at
Griffin Hospital opened in 2011 and primarily serves the
Valley and surrounding communities. It combines state-of-the-art
technology, a team of highly trained physicians and staff, and a
Planetree healing environment to offer patients a comprehensive range of
personalized breast care and wellness services.
The Hewitt Center for Breast Wellness features two new, state-of-the-art digital mammography suites with 3D mammography (tomosynthesis) capability, a breast ultrasound suite, and the most advanced system available to perform stereotactic biopsy.
The Center also utilizes a rapid diagnostic model where patients are often given test results the same day imaging tests are performed, and if indicated, follow up testing (ultrasound, breast biopsy) and even consultation with a breast surgeon are often available the same day if the patient’s schedule permits.
For information, call 203-732-1300 or visit griffinhealth.org/cbw.
The Hewitt Center for Breast Wellness features two new, state-of-the-art digital mammography suites with 3D mammography (tomosynthesis) capability, a breast ultrasound suite, and the most advanced system available to perform stereotactic biopsy.
The Center also utilizes a rapid diagnostic model where patients are often given test results the same day imaging tests are performed, and if indicated, follow up testing (ultrasound, breast biopsy) and even consultation with a breast surgeon are often available the same day if the patient’s schedule permits.
For information, call 203-732-1300 or visit griffinhealth.org/cbw.
About Phenogen Sciences
BREVAGen is supplied by Phenogen Sciences,
a subsidiary of Genetic Technologies Limited. Phenogen Sciences, the
U.S. subsidiary of Australia-based Genetic Technologies Limited, is a
pioneer in personalized healthcare. Phenogen offers novel predictive
testing and assessment tools that help physicians proactively manage
women’s health risks. For more information, visit phenogensciences.com.
About Genetic Technologies Limited
Genetic Technologies is an established
diagnostics company with more than 20 years of experience in
commercializing genetic testing, non-coding DNA and product patenting.
The company has operations in Australia and the U.S. and is dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets.
For information, visit gtglabs.com.
This is a press release from Griffin Hospital.
The company has operations in Australia and the U.S. and is dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic Technologies is focused on the commercialization of its patent portfolio through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics assets.
For information, visit gtglabs.com.
This is a press release from Griffin Hospital.
No comments:
Post a Comment